PRISM MarketView

Meta Has Shown Entravision the Exit Amongst Other Advertisers, EVC Shares Drop 50%

New York, March 06, 2024 - PRISM MarketView - Yesterday, PRISM AdTech and Media Index laggard, Entravision Communications (EVC) announced Q4 and FY2023 earnings that was mostly overshadowed by sharing Meta Platform’s (META) decision to wind down its global authorized sal...

6 March 2024

Lipella to Advance Oral Graft-versus-Host-Disease Candidate

New York, N.Y., March 06, 2024 - PRISM MarketView - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) has received FDA approval of an Investigational New Drug (IND) application for clinical testing of LP-410 in the treatment of oral Graft-Versus-Host Disease (GvHD). Lipella ex...

6 March 2024

PRISM Psychedelics Index: atai Life Sciences Doses First Patient in Psychedelic Treatment Trial

New York, N.Y., March 06, 2024 - PRISM MarketView - Biopharmaceutical company, atai Life Sciences (Nasdaq: ATAI) joined the PRISM MarketView Emerging Psychedelics Index this week. The company was founded in response to the significant unmet need and lack of innovation in...

6 March 2024

SKYX Partners with Golden Lighting to Bring Smart Plug & Play Products to New Sales Channels

New York, March 06, 2024 - PRISM MarketView - SKYX Platforms Corp. (Nasdaq: SKYX) will partner with Golden Lighting, a leading elegant lighting company and manufacturer. The collaboration will enable SKYX to showcase its disruptive smart and advanced plug & play prod...

6 March 2024

IceCure’s ProSense® Delivers 100% Tumor Reduction in Early-Stage Breast Cancer

New York, N.Y., March 06, 2024 - PRISM MarketView - IceCure Medical Ltd. (Nasdaq: ICCM) has announced new data from a preliminary, independent breast cancer study showing median tumor reduction of 100% at six and 12 months following cryoablation in women deemed inoperabl...

6 March 2024

NRx Awaits Topline Data in Suicidal Bipolar Depression Treatment Trial

New York, N.Y., March 04, 2024 - PRISM MarketView - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has reached the ‘Last Patient, Last Visit’ milestone in its Phase 2b/3 Trial of NRX-101 in suicidal treatment resistant bipolar depression. The company announced that the 74th an...

5 March 2024

Quoin Pharmaceuticals to Include Teen Patients in Rare Disease Clinical Trials

New York, N.Y., March 04, 2024 - PRISM MarketView - Clinical stage biotechnology company, Quoin Pharmaceuticals (Nasdaq: QNRX) has received FDA clearance to recruit subjects aged 14 years and older into its two ongoing clinical trials for QRX003, which is being evaluated...

4 March 2024

AI Brings 20/20 to 2024: TSA Precheck & Airlines Rolling Out “Touchless ID”, BBAI Trades Up ~30% on Today’s “Vision AI” Acquisition News.

New York, N.Y., March 04, 2024 - PRISM MarketView -Boarding passes or IDs will be replaced by “Touchless ID” technology for United Airlines (UA) passengers traveling through Chicago O’Hare and Los Angeles International airports. The program will continue to roll out acro...

4 March 2024

Seaport Global Believes in A Buy, Upgrades Its Rating on fubuTV (FUBO)

New York, N.Y., March 04, 2024 - PRISM MarketView - On Monday, Seaport Global Securities upgraded its rating on fuboTV (FUBO) shares from Neutral to Buy, with a new price target of $2.50. The move came after the company’s stock initially surged 17% last Friday following ...

4 March 2024

NeuroBo Pharmaceuticals to Initiate Clinical Trial in Obesity

New York, N.Y., March 04, 2024 - PRISM MarketView - NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has received Institutional Review Board (IRB) approval to proceed with its Phase 1 clinical trial of DA-1726 for the treatment of obesity. The company expects to randomize th...

4 March 2024